Ludwig Enterprises, Inc., a U.S.-based biotechnology company, has announced Revealia™, a new tool that could change how cancer is detected. The company describes Revealia™ as a simple, non-invasive cheek swab that people can order by mail to help detect early signs of cancer.
The science behind Revealia™ is called the Revealia Inflammatory Index. It uses artificial intelligence to analyze mRNA, a type of genetic material, to assess cancer risk. According to Ludwig Enterprises, this AI technology gets smarter over time by learning from more and more patient data, allowing it to improve how it detects cancer.
The tool is designed to strike a balance between sensitivity (how well it identifies real cancer cases) and specificity (how well it avoids false positives). It’s currently being used in over 40 medical clinics across the United States, and its AI continuously updates its understanding of genetic signals linked to cancer.
Marvin S. Hausman, MD, Chief Scientific Officer at Ludwig, highlighted the significance of the technology. “We’ve uncovered important mRNA-based genetic signals that can indicate the presence of cancer,” he said. “With Revealia™, we’re hoping to make early detection easier and more effective.”
Kyle Ambert, a member of Ludwig’s Scientific Advisory Board and an AI expert, added that the technology’s ability to learn and adapt is key. “As our dataset grows, the AI gets better at identifying the subtle signs of cancer. This dynamic approach is what makes Revealia™ so promising,” he explained.
Ludwig Enterprises has made it clear that their mission is to offer more accessible and reliable cancer screening tools. The company is focused on using new technology to help combat diseases linked to chronic inflammation, like cancer and heart disease, which are among the leading causes of death globally.